[
    [
        {
            "time": "2021-08-26",
            "original_text": "A股融资融券日报：两融余额增加5.84亿元（8月26日）",
            "features": {
                "keywords": [
                    "两融余额",
                    "增加"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加5.84亿元（8月26日）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "沃森生物上半年净利润3.2亿同比增超4倍，mRNA新冠疫苗已处于III期临床阶段",
            "features": {
                "keywords": [
                    "沃森生物",
                    "净利润",
                    "同比增",
                    "mRNA新冠疫苗",
                    "III期临床"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物上半年净利润3.2亿同比增超4倍，mRNA新冠疫苗已处于III期临床阶段",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "沃森生物：上海泽润在北京设立全资子公司 投建重组新型冠状病毒疫苗(CHO细胞)产业化项目",
            "features": {
                "keywords": [
                    "沃森生物",
                    "上海泽润",
                    "全资子公司",
                    "重组新冠疫苗",
                    "产业化项目"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物：上海泽润在北京设立全资子公司 投建重组新型冠状病毒疫苗(CHO细胞)产业化项目",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "沃森生物：拟投建重组新型冠状病毒疫苗（CHO细胞）产业化项目",
            "features": {
                "keywords": [
                    "沃森生物",
                    "重组新冠疫苗",
                    "产业化项目"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物：拟投建重组新型冠状病毒疫苗（CHO细胞）产业化项目",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "沃森生物与蓝鹊生物共同开展流感病毒mRNA疫苗产品开发及商业化合作",
            "features": {
                "keywords": [
                    "沃森生物",
                    "蓝鹊生物",
                    "流感病毒mRNA疫苗",
                    "产品开发",
                    "商业化合作"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物与蓝鹊生物共同开展流感病毒mRNA疫苗产品开发及商业化合作",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "沃森生物：上半年净利润同比增419% 加快新冠疫苗的临床和产业化进度",
            "features": {
                "keywords": [
                    "沃森生物",
                    "净利润",
                    "同比增",
                    "新冠疫苗",
                    "临床",
                    "产业化"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物：上半年净利润同比增419% 加快新冠疫苗的临床和产业化进度",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "沃森生物上半年净利升419.09%至3.19亿元",
            "features": {
                "keywords": [
                    "沃森生物",
                    "净利",
                    "同比升",
                    "3.19亿元"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物上半年净利升419.09%至3.19亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "沃森生物半年报：上半年净利3.19亿元 同比增419%",
            "features": {
                "keywords": [
                    "沃森生物",
                    "半年报",
                    "净利",
                    "同比增",
                    "3.19亿元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物半年报：上半年净利3.19亿元 同比增419%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-25",
            "original_text": "沃森生物：签署呼吸道合胞病毒mRNA疫苗产品开发及商业化合作协议",
            "features": {
                "keywords": [
                    "沃森生物",
                    "呼吸道合胞病毒",
                    "mRNA疫苗",
                    "产品开发",
                    "商业化合作"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物：签署呼吸道合胞病毒mRNA疫苗产品开发及商业化合作协议",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]